Associate Director / Director, Global Value & Access (GV&A)

Commercial Cambridge, MA


Description

What's in it for you?

Acceleron is seeking a technically strong and innovative HEOR and market access professional who will contribute to the development of the access value and evidence plan, develop the value proposition and messages, and to bring insights on payer evidence requirements for our Clinical, R&D, and Medical Affairs teams. This individual will have responsibilities for Sotatercept, lead Pulmonary hypertension asset that has achieved BTD status in the US and PRIME designation in EMEA.  In addition, individual will also be responsible for the data generation plan comprising (but not limited to) the development of an HEOR plan, publication planning, contribution to health economic model development, indirect comparison analyses and RWE evidence development for Sotatercept.

 

What will you be doing?

  • Jointly with the Global Value and Access (GV&A) Senior Director build a market access and value plan for Sotatercept from Phase II to launch
  • Conduct payer and market access stakeholder advisory boards in the US and Europe to drive insights into development of Sotatercept
  • Engage with national, regional and local payers, clinicians and HEOR experts and advisors on 1:1 meetings to drive the value and HEOR evidence plan for Sotatercept
  • Conduct HTA-/reimbursement-specific trial data analyses, PRO strategy development and inclusion in the trial program
  • Develop Sotatercept’s global value and AMCP dossiers, value proposition and messages and validate messages with external stakeholders
  • Lead literature reviews, develop necessary RWE, conduct modeling and indirect comparison activities, develop and execute on the accompanying publication strategy
  • Participate in the rapid response team for Sotatercept with Global Access and Pricing portfolio lead

 

This position reports to the Senior Director, Global Value and Access - Sotatercept

What are we looking for?

  • Requires an advance degree (MS, MPH, or PhD) in health economics & outcomes research (HEOR), health services research, and/or HEOR Fellowship
  • 6-8 years (with master’s degree) and 3-5 years (with terminal degrees) of relevant HEOR and market access experience in a biotech or pharmaceutical company or related consulting services, enough to have developed a deep understanding of the global Health Technology Assessment (HTA) markets
  • Experience in leading the access planning and value development activities for orphan/rare diseases is preferred
  • Strong publication record in peer-reviewed journals and/or congresses
  • Experience in supporting development phase as well as launch-phase assets is preferred
  • Ability to operate independently in cross-functional matrix environment with proven ability to build relationships, collaboration and teamwork across functions
  • Demonstration of strong strategic thinking skills, as evidenced by the ability to identify alternative scenarios and resulting implications
  • Strong understanding of payer environment in the US and/or Europe, including commercial payers as well as Medicare, health technologies assessment, and health policy and ability to tailor strategies to a diverse set of payer archetypes
  • Manages project budget to effectively generate the reimbursement and HEOR evidence to support value proposition of pulmonary assets
  • New product launch experience preferred
  • Strong written and verbal communication influencing skills


How will you grow with us?

 This position will allow you to join a growing and advancing company with an active pipeline as we expand our Global presence.  As a part of a small, yet dynamic team, you will have the opportunity to quickly build ownership in your role and seek new opportunities for growth as we prepare to take products through the clinic to commercialization.  If you are looking to be a part of an innovative and fast-paced environment, join our team!

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair. Acceleron focuses its research, development, and commercialization efforts in pulmonary and hematologic diseases. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial. The Company is currently planning multiple Phase 3 trials with the potential to support its long-term vision of establishing sotatercept as a backbone therapy for patients with PAH at all stages of the disease. Acceleron is also investigating the potential of its early-stage pulmonary candidate, ACE-1334, which it plans to advance into a Phase 1b/2 trial in systemic sclerosis-associated interstitial lung disease (SSc-ILD) next year. In hematology, REBLOZYL® (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the United States and are also developing luspatercept for the treatment of anemia in patient populations of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.